Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bolen

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Immunology (Baltimore, Md. : 1950)|February 10, 2017
Multicenter Systems Analysis of Human Blood Reveals Immature Neutrophils in Males and During PregnancyJana Blazkova, Sarthak Gupta, Yudong Liu, et al.
Blood|January 9, 2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCLMagdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, et al.
Nature Medicine|January 17, 2017
Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological statesDavid Furman, Junlei Chang, Lydia Lartigue, et al.
Blood|October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesLaurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Blood Advances|July 29, 2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphomaJonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2020
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III StudyArnon P Kater, Jenny Qun Wu, Thomas Kipps, et al.
Blood Advances|July 29, 2021
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatmentMalgorzata Nowicka, Laura K Hilton, Margaret Ashton-Key, et al.
Nature|May 4, 2017
Non-equivalence of Wnt and R-spondin ligands during Lgr5<sup>+</sup> intestinal stem-cell self-renewalKelley S Yan, Claudia Y Janda, Junlei Chang, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Immunology (Baltimore, Md. : 1950)|February 10, 2017
Multicenter Systems Analysis of Human Blood Reveals Immature Neutrophils in Males and During PregnancyJana Blazkova, Sarthak Gupta, Yudong Liu, et al.
Blood|January 9, 2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCLMagdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, et al.
Nature Medicine|January 17, 2017
Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological statesDavid Furman, Junlei Chang, Lydia Lartigue, et al.
Blood|October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesLaurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Blood Advances|July 29, 2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphomaJonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2020
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III StudyArnon P Kater, Jenny Qun Wu, Thomas Kipps, et al.
Blood Advances|July 29, 2021
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatmentMalgorzata Nowicka, Laura K Hilton, Margaret Ashton-Key, et al.
Nature|May 4, 2017
Non-equivalence of Wnt and R-spondin ligands during Lgr5<sup>+</sup> intestinal stem-cell self-renewalKelley S Yan, Claudia Y Janda, Junlei Chang, et al.
Pageof 5